Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 29, 2017. The filing discloses a significant capital market transaction involving the pricing of senior notes and the execution of an underwriting agreement.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company priced $750 million of 3.45% Senior Notes due December 15, 2027, and $500 million of 4.30% Senior Notes due December 15, 2047.
- Total Principal: $1.25 billion aggregate principal amount.
- Net Proceeds: Estimated at approximately $1.235 billion after deducting underwriting discounts and offering expenses.
- Closing Date: Expected on December 4, 2017.
- Existing Debt Status: As of September 30, 2017, there were no borrowings outstanding under the Company's multi-currency revolving credit facility.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations to fund strategic initiatives. The Company intends to use the net proceeds for the following purposes:
- Financing a portion of the proposed acquisition of H.D. Smith.
- Paying related fees and expenses associated with the acquisition.
- Redeeming all of its 4 7/8% Senior Notes due November 15, 2019.
- General corporate purposes.
Pending the use of these proceeds, the Company intends to invest in institutional money market funds, U.S. government securities, certificates of deposit, or other short-term interest-bearing securities.
Guidance, Risks, and Contingencies
Contingencies: The Notes offering is not contingent on the consummation of the H.D. Smith acquisition. However, if the acquisition is not completed by May 20, 2018, or if the agreement is terminated prior to that date, the 2047 Notes are subject to mandatory redemption at 101% of the aggregate principal amount plus accrued interest.
Risks and Forward-Looking Statements: Management highlighted numerous risks that could cause actual results to differ from projections, including:
- Unfavorable trends in pharmaceutical pricing and reimbursement rates.
- Regulatory changes regarding controlled substances and opioid abuse.
- Legal proceedings and potential litigation costs.
- Risks associated with the integration of H.D. Smith and PharMEDium.
- Interest rate and foreign currency exchange rate fluctuations.
Investor Verification Checklist
- Verify the final closing date of the Notes offering (expected December 4, 2017) and the actual net proceeds received.
- Confirm the status of the H.D. Smith acquisition and whether the May 20, 2018 deadline is met to avoid mandatory redemption of the 2047 Notes.
- Review the redemption terms and execution of the 4 7/8% Senior Notes due 2019.
- Monitor regulatory approvals required for the H.D. Smith acquisition.
- Assess the impact of the new debt load on the Company's leverage ratios and liquidity position.